News

An expanded access program has been opened to allow patients with ALS access to BHV-0223, a sublingual formulation of riluzole, all while Biohaven Pharmaceutical prepares a new drug application for the drug.

With approximately 500 board-certified headache specialists and just over 60 million Americans with headache, the average wait time to see one of us is 3 to 4 months. Technology may hold the key to issues such as this.

Watching events unfold when humans are subject to public embarrassment can lead to vicarious feelings-and change activity in the brain.

The group medical director of neuroscience at Genentech discussed the history of a well-known therapy for multiple sclerosis: ocrelizumab (Ocrevus).

A non-invasive vagus nerve stimulation therapy significantly improved pain-free rates compared with a sham device for patients with episodic cluster headache and migraines.

The disease-modifying therapy showed significant improvements in 4 TSQM measures for patients with relapsing multiple sclerosis.

The associate professor of clinical neurology spoke about the need to understand modifiable social and cultural factors that could impact disease severity and progression.

The clinical director of the Anti-NMDA Receptor Encephalitis Foundation spoke about the insidiousness of AD and the need for diagnosis earlier in disease progression.

The announcement was discouraging to many, as only 2 agents for ALS have been granted FDA approval in as many decades.

The UC Health professor of neurology argued that with the current view on Parkinson disease, the field is missing the mark for disease-modifying interventions.

The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.

More than two-thirds of patients treated with intravenous infusions of the CGRP inhibitor eptinezumab had an average 50% reduction in migraines.

Study findings revealed statistically significant results at week 4 for the 100-U dose compared to placebo. The 75-U dose, while effective, did not achieve statistical significance.

The data from the phase III EXPAND study indicated to the researchers that this risk reduction obtained with siponimod was substantially isolated from MS relapse.

Chronic traumatic encephalopathy is a neurodegenerative disease that is believed to be a consequence of exposure to repetitive head impacts, including concussions and subconcussive injuries.

In 3 clinical trials including more than 300 patients, the oral solution resulted in significant reductions in seizures for patients with both epileptic conditions.

When and why were the Beers criteria set in place? Learn more in this quiz.

Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.

The calcitonin gene-related peptide inhibitor lowered monthly migraine days by ≥50% in 30.3% of patients compared to 13.7% on placebo.

A photographic memory with low resolution images.

Here: the most notable changes in the new AAN guideline on mild cognitive impairment.

The program seeks to optimize small-molecule compounds to decrease the production of mHtt through PTC’s splicing platform.

This is a unique opportunity for talented early career psychiatrists and neurologists to gain experience in scholarly activities and research.

Using the NCT-504 compound to inhibit cell-signaling activity in PIP4Kγ resulted in an increase in autophagy in connective tissue cells from patients with HD.

Vagus nerve stimulation in conjunction with conventional rehabilitation services more than doubled lasting recovery in forelimb supination and simple motor tasks following a stroke.

What's the link between restrictive anorexia, anorexia nervosa, and binge eating disorder and ASD? This study sheds some light.

Alterations in the gut microbiome may trigger autoimmunity against the CNS, and contribute to the development of neuropsychiatric disorders. How? A recent review offers insights.

The treatment is the first patient-infused subcutaneous formulation of immunoglobulin to gain approval for CIDP.

Epilepsy appears to be the main reason for an increased risk of serious traffic accidents among patients with the disease -not anti-epileptic drugs.

Exposure to monesin has been shown to combat stress by oxidants and free radicals via the protein kinase R-like endoplasmic reticulum kinase/activating transcription factor 4 pathway.